New horizons for structure-based discovery of PYCR1 inhibitors

Read full text Summarise with VIRAT
Authors: Wiktoria Ragin-Oh, Dominika Czerwonka, H. L. Tran, Milosz Ruszkowski
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Recent years have seen mounting evidence linking proline metabolism to cancer cell survival, proliferation, and metastasis.In the final step of proline biosynthesis, δ¹-pyrroline-5-carboxylate (P5C) reductase catalyzes the NAD(P)H-dependent conversion of P5C to proline.Among the three human P5C reductase isoforms-PYCR1, PYCR2, and PYCR3-PYCR1 has emerged as a particularly attractive therapeutic target.Since 2019, over 100 studies have associated elevated PYCR1 expression with poor prognosis across numerous cancer types.Functional studies further support its role in malignancy: PYCR1 knockdown or knockout reduces proliferation, impairs tumor growth, and induces cell cycle arrest and apoptosis.These findings are consistent with a large-scale 2014 transcriptomic analysis, which ranked PYCR1 among the most consistently overexpressed metabolic enzymes in tumors across 19 cancer types.

Fields of Study & Subjects

Amino Acid Enzymes and Metabolism Computational Drug Discovery Methods Enzyme Structure and Function

Publication details

Journal / source
Acta Crystallographica Section A Foundations and Advances
Volume
81
Issue
a1
Pages
e44–e44
Publication date
30 March 2026
Language
EN